Advance acquired the former Sanofi U.S. Research and Development Campus in Bridgewater, New Jersey . The Campus encompasses approximately 1.2 million square feet of lab, office, and GMP production facilities, as well as a full service cafeteria, fitness center and conference facilities. Advance successfully executed on its business plan of re-tenanting approximately 800,000 square feet of state-of-the-art lab and office space. Prominent R&D tenants include Nestle Health Science, Ashland, Amneal Pharmaceuticals, Avantor, Solaris, Matinas Biopharm, Nevakar, ClinicalGenomics, GSG Scientific, Unionmed Tech, and 3D Biotek. The campus offers immediate access to Routes 202 and 206, and easy access to I-78, I-287. In addition, the campus features top corporate amenities, and is close to shopping, restaurants, hotels, and daycare.
Advance Realty Investors acquired the former Sanofi U.S. Research and Development Campus in Bridgewater, New Jersey. The campus encompasses approximately 1.2 million square feet of lab, office, and GMP production facilities, as well as a full-service cafeteria, fitness center, and conference facilities. Advance successfully executed on its business plan of re-tenanting approximately 800,000 square feet of state-of-the-art lab and office space. Advance led the successful sale process of the campus in 2020.
In 2017, Advance was designated the Redeveloper after the campus was identified as an Area in Need of Redevelopment. The redevelopment area, totaling approximately 62 acres, received both zoning and site plan approvals for a portion of the site.
In 2022, Advance successfully negotiated a Settlement Agreement with the Township of Bridgewater, outlining a development program that includes:
250,000 SF of logistics/warehouse space
650,000 SF of life science lab/office space
10,000 SF of retail/restaurant space
Buildings 1 & 2: Logistics
Building 5: Potential build-to-suit opportunity
Key Milestones:
Site Plan Application: Q1 2023
Redevelopment Agreement Finalization: March/April 2023
Site Plan Approval: Q2 2023
